Rap1 GTPase Inhibits Tumor Necrosis Factor-α–Induced Choroidal Endothelial Migration via NADPH Oxidase– and NF-κB–Dependent Activation of Rac1 by Wang, Haibo et al.
The American Journal of Pathology, Vol. 185, No. 12, December 2015ajp.amjpathol.orgGROWTH FACTORS, CYTOKINES, AND CELL CYCLE MOLECULESRap1 GTPase Inhibits Tumor Necrosis
Factor-aeInduced Choroidal Endothelial
Migration via NADPH Oxidasee
and NF-kBeDependent Activation of Rac1
Haibo Wang,* Lori Fotheringham,* Erika S. Wittchen,y and M. Elizabeth Hartnett*From The John A. Moran Eye Center,* University of Utah, Salt Lake City, Utah; and the Department of Cell Biology and Physiology,y University of North





M. Elizabeth Hartnett, M.D.,
University of Utah, 65 N Mario
Capecchi Dr, Salt Lake City,
UT 84132. E-mail: me.
hartnett@hsc.utah.edu.opyright ª 2015 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2015.08.017Macrophage-derived tumor necrosis factor (TNF)-a has been found in choroidal neovascularization (CNV)
surgically removed from patients with age-related macular degeneration. However, the role of TNF-a in
CNV development remains unclear. In a murine laser-induced CNV model, compared with un-lasered
controls, TNF-a mRNA was increased in retinal pigment epithelial and choroidal tissue, and TNF-a
colocalized with lectin-stained migrating choroidal endothelial cells (CECs). Inhibition of TNF-a with a
neutralizing antibody reduced CNV volume and reactive oxygen species (ROS) level around CNV. In CECs,
pretreatment with the antioxidant apocynin or knockdown of p22phox, a subunit of NADPH oxidase,
inhibited TNF-aeinduced ROS generation. Apocynin reduced TNF-aeinduced NF-kB and Rac1 activation,
and inhibited TNF-aeinduced CEC migration. TNF-aeinduced Rac1 activation and CEC migration were
inhibited by NF-kB inhibitor Bay11-7082. Overexpression of Rap1a prevented TNF-aeinduced ROS
generation and reduced NF-kB and Rac1 activation. Activation of Rap1 by 8-(4-chlorophenylthio)
adenosine-20-O-Me-cAMP prevented TNF-aeinduced CEC migration and reduced laser-induced CNV
volume, ROS generation, and activation of NF-kB and Rac1. These findings provide evidence that
active Rap1a inhibits TNF-aeinduced CEC migration by inhibiting NADPH oxidase-dependent NF-kB
and Rac1 activation and suggests that Rap1a de-escalates CNV development by interfering with ROS-
dependent signaling in several steps of the pathogenic process. (Am J Pathol 2015, 185: 3316e3325;
http://dx.doi.org/10.1016/j.ajpath.2015.08.017)Supported by NIH grants EY014800, R01 R01EY015130, and
R01EY017011 (M.E.H.), March of Dimes grant 6-FY13-75 (M.E.H.), and
Research to Prevent Blindness, Inc., New York, NY, grant to the Depart-
ment of Ophthalmology and Visual Sciences, University of Utah.
Disclosures: None declared.
Portions of these data were presented in oral form at the American
Ophthalmological Society annual meeting held May 14-17, 2015, in
Newport, RI.Neovascular age-related macular degeneration (AMD) is the
leading cause of legal blindness in people >60 years.1
Intravitreal injection of antievascular endothelial growth
factor (VEGF) agents has become the standard of care for
choroidal neovascularization (CNV) in neovascular AMD;
however, reports indicate approximately 40% of patients
with neovascular AMD respond to anti-VEGF treatment.2
One reason may be that treatment is provided too late
when CNV is already present. To address this possibility,
we focus on understanding early steps in the pathophysi-
ology in neovascular AMD to prevent vision loss. Activa-
tion and migration of choroidal endothelial cells (CECs) are
early steps in the development of CNV. Activated CECs
migrate through the Bruch membrane toward the retinalstigative Pathology.
.
pigment epithelium (RPE) and also transmigrate the RPE
into the sensory retina. At either location, activated CECs
can proliferate to form CNV. Severe vision loss occurs
when CNV develops in the sensory retina.3,4
Both inflammation and oxidative stress have been
implicated in the development of CNV.5 The inflammatory
Rap1 Inhibits TNF-aeInduced ROS Signalscytokine, tumor necrosis factor (TNF)-a, was found in
macrophages within CNV surgically removed from patients
with neovascular AMD.6 Inhibition of TNF-a bioactivity by
neutralizing antibodies7 or by targeting TNF-a receptor 18
reduced the volume and leakage of laser-induced CNV in
experimental models, suggesting that TNF-aemediated
signaling was important in the development of CNV.9,10
The roles of TNF-aemediated inflammation in rheuma-
toid arthritis, Alzheimer disease, atherosclerosis, and dia-
betes have been well established,11 and activation of NF-kB
by TNF-a plays a fundamental role in these chronic in-
flammatory diseases.12 Recent studies also provide evidence
to support the role of TNF-a in the regulation of oxidative
stress. In microglia cells, TNF-a induced mitochondrial
reactive oxygen species (ROS) generation.13 In coronary
microvascular endothelial cells (ECs), TNF-aeinduced ROS
generation was blocked in cells depleted of p47phox/, a
subunit of NADPH oxidase,14 suggesting that NADPH
oxidase was involved in the TNF-aemediated ROS genera-
tion. Additional evidence in dermal microvascular ECs
indicated that activation of NF-kB, a downstream effector of
TNF-aemediated inflammatory signaling, was involved in
TNF-aeinduced ROS generation and involved NADPH
oxidase activation.15 In aortic vascular ECs, cross talk be-
tween oxidative and inflammatory pathways was proposed to
affect endothelial dysfunction and cardiovascular disease.16
We previously found that VEGF promoted CEC migra-
tion by activating the small GTPase Rac1.17,18 Inhibition of
Rac1 activity through molecular or pharmacological ap-
proaches prevented VEGF-induced CEC migration and also
reduced ROS generated by NADPH oxidase.19 We then
found that activation of another GTPase protein, Rap1,
increased RPE barrier integrity and reduced CNV volume
in a murine laser injury model by inhibiting NADPH
oxidaseedependent ROS generation in RPE.20,21 Herein,
we study another pathway that involves ROS generation
through the inflammatory cytokine TNF-a, specifically
testing the hypothesis that TNF-a induces CEC migration
via NADPH oxidaseegenerated ROS, in which activation
of Rac1 is downstream of ROS, and that activation of Rap1
prevents TNF-aeinduced CEC migration by reducing ROS
generation. On the basis of previous studies in other tissues,
we postulate that interactions between inflammatory and
oxidative signaling mechanisms overwhelm homeostatic
mechanisms in the outer retina, which would normally
prevent the formation of CNV. Through at least two inter-
connected signaling pathways that augment CEC migration,
CNV can develop, such as that in neovascular AMD.
Materials and Methods
Animals
C57/BL/6 wild-type female mice, aged 5 to 8 weeks, were
used (Charles River, San Diego, CA). All animal procedures
were conducted in accordance with the University of UtahThe American Journal of Pathology - ajp.amjpathol.org(Salt Lake City, UT) for the Guide for the Care and Use of
Laboratory Animals22 and the Association for Research in
Vision and Ophthalmology Statement for the Use of Ani-
mals in Ophthalmic and Vision Research.
Laser-Induced CNV Model and Injections
The laser-induced CNV model was used as previously
described.19 The i.p. injections of 100 mg/kg ketamine
(Hospira, Inc., Lake Forest, IL) and 20 mg/kg xylazine
(AnaSed Lloyd Laboratories, Shenandoah, IA) were used for
anesthesia. After mydriasis with 1% tropicamide ophthalmic
solution (Bausch & Lomb, Rochester, NY), mice were raised
onto a platform, and a coupling agent, GenTeal (Alcon, Fort
Worth, TX), was applied to the cornea (Novartis, East Han-
over, NJ). Laser photocoagulation was performed (532-nm
diode laser, 400-mW intensity, 100-millisecond duration;
Iridex, Mountain View, CA) using the laser module of the
Phoenix Micron IV Imaging System (Phoenix Research
Labs, Pleasanton, CA). Five to six laser spots per eye were
applied approximately two disk diameters from the optic
nerve, avoiding major vessels. Disruption of the Bruch
membrane was confirmed by the appearance of a cavitation
bubble. Right after laser injury, using a Microliter syringe
(Hamilton Company, Reno, NV), an i.v. injection of total
volume of 1 mL of 20.5 mmol/L 8-(4-chlorophenylthio)
adenosine-2-O-Me-cAMP (8CPT; Calbiochem, La Jolla,
CA)20 and/or 50 ng/mL neutralizing anti-mouse TNF-a
antibody (Ab; R&D Systems, Minneapolis, MN) and 50 ng/
mL control isotype IgG (R&D Systems) or phosphate-
buffered saline (PBS). The i.v. 8CPT injections can access
CNV and increase Rap1 activity in RPE/choroids.20 Groups
with different injections were 0.5 mL PBS þ 0.5 mL IgG, 0.5
mL 8CPT þ 0.5 mL IgG, 0.5 mL TNF-a Ab þ 0.5 mL PBS,
and 0.5 mL TNF-a Ab þ 0.5 mL 8CPT. Both eyes of each
mouse were lasered and injected with the same reagent. Five
days after laser, mice were euthanized and one eye from each
mouse was collected for RPE and choroidal flat mount
analysis and the fellow eye for dihydroethidium (DHE;
Invitrogen, Carlsbad, CA) fluorescence staining of RPE/
choroids or for protein analyses by immunostaining of cho-
rioretinal sections or Western blot analysis. Each group
included both eyes of eight mice.
Analysis of Lesion Volume in RPE/Choroidal Flat
Mounts
Eyes were first fixed in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA) for 1 hour. After
removal of cornea, lens, retina, and vitreous, posterior
eyecups of the RPE, choroid, and sclera were dissected.
Eyecups were stained with AlexaFluor 568econjugated
isolectin B4 (Invitrogen) overnight at 4C to label invading
choroidal vessels. The eyecups were then flattened by cut-
ting radial incisions and flat mounted onto a microscope
slide with Fluoromount G (Southern Biotech, Birmingham,3317
Wang et alAL) for confocal imaging. Flat mounts were imaged by
taking optical Z-sections at 5-mm increments with a confocal
microscope (FV1000; Olympus, Tokyo, Japan). Each CNV
lesion volume (mm3) was measured by computerized image
analysis using Fluoview software version 4.1 provided with
the microscope. Lesions with obvious hemorrhage or
bridging CNV were excluded. Each CNV spot was
considered an independent data point. For each condition, at
least 25 spots were analyzed from eight different mice.
ROS Generation Assay in RPE/Choroidal Sections
Surrounding CNV Lesions by DHE Staining
ROS generation in RPE/choroids was detected by measuring
DHE fluorescence, as previously described.19 Briefly, fresh-
frozen sections of RPE-choroids were thawed, washed in
Tris-buffered saline, and incubated with 10 mmol/L DHE in
the dark at 37C for 15 minutes. Slides were rinsed and
mounted with DAPI Fluoromount-G (SouthernBiotech,
Birmingham, AL) mounting medium. Images were acquired
with a confocal microscope (Olympus). The area of the lesion
and neovascular tissue in laser-burned sections and the in-
tegrated density of DHE staining per image area of interest
were measured using ImageJ version 1.43 (NIH, Bethesda,
MD; http://imagej.nih.gov/ij). The integrated densities of
sections of CNV from several mice were analyzed for each
condition. For each condition, at least 10 spots were analyzed
from four different mice.
Preparation and Immunostaining of Retinal and
RPE/Choroidal Sections
Eyes were first fixed in 4% paraformaldehyde for 1 hour, and
then corneas and lenses were removed. Eye cups were incu-
bated in 30% sucrose overnight and frozen at 80C after
immersion in OCT compound (Tissue Tek; EMS, Hatfield,
PA). Eye cups were cut into cryosections (12 mm thick).
Sections were incubated with either mouse antieGTP-Rac1
(1:100; NewEast Biosciences, King of Prussia, PA) or antie
p-p65 (1:100; Cell Signaling Technology, Danvers, MA)
overnight at 4C. After rinsing, sections were incubated for 1
hour with fluorescein isothiocyanateeconjugated goat anti-
mouse secondary Ab (1:100; Jackson ImmunoResearch Lab-
oratories, Inc., West Grove, PA) and Alexa 568econjugated
Ab for isolectin B4 (lectin, 1:500; Invitrogen) to stain vessels.
Sections stained with isotype IgG were used as controls. La-
beling for all sections was performed during the same exper-
imental session. Images were captured using confocal
microscopy (model IX81; Olympus) at 20 magnification.
Cell Culture
Human CECs were isolated from different donor eyes obtained
from Utah Zions Eye Bank (Salt Lake City, UT), as described
previously.18 CECs were grown in endothelial growth medium3318(Lonza, Walkersville, MD) plus 5% fetal bovine serum, and
cells from passages 2 to 5 were used for experiments.
Adenoviral Transduction and siRNA Transfection of CECs
CECs were transduced with adenoviral constructs express-
ing green fluorescent protein (Ad-GFP) or GFP-tagged
active Rap1a (Ad-63E), kind gifts from Dr. Keith
Burridge (University of North Carolina, Chapel Hill, NC),
or transfected using Lipofectamine 2000 per commercial
protocol (Life Technologies, Grand Island, NY) with siRNA
targeting the human CYBA gene, Rac1 gene, or silencer-
selective negative control siRNA (all from Life Technolo-
gies, Grand Island, NY). Forty-eight hours after viral
transduction or transfection, cells were incubated with 20
ng/mL human recombinant TNF-a (R&D Systems) or PBS
for 30 minutes for further analyses.
ROS Generation Assay in Cultured CECs
Intracellular ROS generation was measured as described
previously.21 CECs were loaded with 5-mm 20,70-dichloro-
fluorescein (DCF; Invitrogen) in serum-free medium for 30
minutes at 37C. After two washes with PBS, cells were
pretreated with 100 mmol/L apocynin (Sigma-Aldrich, St.
Louis, MO) or PBS for 30 minutes, then incubated with 20
ng/mL TNF-a or PBS for another 30 minutes. ROS gen-
eration was measured in a fluorescent plate reader at an
excitation of 488 nm and an emission of 520 nm. Cells
incubated with 10 mmol/L H2O2 were used as a positive
control. For each condition, at least nine samples from three
independent experiments were analyzed.
Pull-Down Assay of Rac1 Activation
CECswere pretreatedwith 100mmol/L apocynin, 1mmol/LBay
11-7082 (Sigma-Aldrich), or dimethyl sulfoxide/PBS control
for 30minutes, then incubatedwith 20 ng/mLTNF-a or PBS for
another 15 or 60 minutes. Cells were harvested for the Rac1
activity assay, as described previously.18 Briefly, cell lysates
were adjusted to equal protein concentration and volumes, and
then incubated for 30 minutes at 4C with 30 mg of glutathione
S-transferasee(Rac1-binding domain of p21 activated kinase 1)
fusion protein (kind gifts fromDr. Keith Burridge) immobilized
on glutathione beads to specifically pull down active (GTP-
bound) Rac1. The amount of active Rac1 versus total Rac1 was
then determined by Western blot analysis with a monoclonal
anti-Rac1 Ab (BD Biosciences, San Jose, CA), followed by a
horseradish peroxidaseeconjugated secondary anti-mouse Ab
(BioRad,Hercules,CA). For each condition, at least six samples
from two or three independent experiments were analyzed.
CEC Migration Assay
Transwell CEC migration assays were performed, as
described previously.23 Growth factorereduced Matrigelajp.amjpathol.org - The American Journal of Pathology
Figure 1 Tumor necrosis factor (TNF)-a mediates choroidal neovascularization and generation of reactive oxygen species around choroidal neo-
vascularization (CNV) in the mouse laser-induced CNV model. A and B: Real-time PCR of mouse TNF-a mRNA in retinal pigment epithelium (RPE)/choroids (A)
and immunostaining of TNF-a in retinochoroidal cryosections of C57Bl/6 6-week-old mice without laser treatment (un-lasered) or 5 days after laser (Lasered)
(B). Red, lectin; blue, DAPI; green, TNF-a; and yellow, lectin þ TNF-a. The arrow points to the area of CNV lesion colabeled with TNF-a and lectin. CeF: CNV
volume (C and D) and dihydroethidium (DHE) staining in RPE/choroids surrounding CNV lesions (E and F) of mice injected with 50 ng isotype IgG (IgG) or 50
ng neutralizing TNF-a antibody (Ab). Representative images of CNV lesions (C) and DHE staining (E); quantification of CNV volume (D) and integrated density
of DHE staining (F). Red, DHE; blue, DAPI; and purple, DHE þ DAPI. The arrow points to the area of CNV lesion. *P < 0.05, **P < 0.01, and ***P < 0.001.
n Z 6 (A); n Z 20 (D). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer.
Rap1 Inhibits TNF-aeInduced ROS Signals(100 mL) with 20 ng/mL human recombinant TNF-a was
plated into each well of a 24-well plate. Two hours later,
500 mL of EBM-2 was added to each well, and a 6.5-mm-
diameter Transwell insert (8-mm pores; Corning Incorpo-
rated, Corning, NY) was placed into the well. Human CECs
in EBM-2 were prestained with Vybrant DiO cell-labeling
solution (Invitrogen) for 30 minutes at 37C and seeded
into the Transwell inserts at 20,000 cells per 200 mL of
EBM-2 media. The plates were incubated for 16 hours at
37C, 5% CO2, and migrated stained CECs were quantified
using fluorescent microscopy. For each condition, at least
six samples were analyzed.
Western Blot Analysis
CECs were lysed in radioimmunoprecipitation assay buffer
(RIPA) with protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN) and orthovanadate (Sigma-Aldrich). Ly-
sates were centrifuged at 16,000  g for 5 minutes at 4C,The American Journal of Pathology - ajp.amjpathol.organd the supernatants were collected. The total protein for
each sample (30 mg in 15 mL) suspended in 4 sample buffer
was loaded into NuPAGE 4% to 12% Bis-Tris Gels (Invi-
trogen) and transferred to a polyvinyl difluoride membrane.
Polyvinyl difluoride membranes were first incubated with
primary Ab to p-p65 (Ser 536; Cell Signaling Technology
Inc., Danvers, MA), total p65 (Cell Signaling Technology
Inc.), or total Rac1 (Transduction Laboratories, Franklin
Lakes, NJ) overnight at 4C by gently rocking and then
incubated for 1 hour with the secondary Ab at room tem-
perature. Densitometry analysis was performed on exposed
films using the software UN-SCAN-IT version 6.1 (Silk
Scientific, Orem, UT).
RNA Isolation and Quantitative PCR Analysis
Total RNA of RPE/choroidal tissues was extracted by TRI
Reagent (Sigma-Aldrich). RNA was quantified using a
NanoDrop spectrophotometer (Thermo Fisher Scientific,3319
Figure 2 Tumor necrosis factor (TNF)-a in-
duces NADPH oxidaseedependent reactive oxygen
species (ROS) generation in choroidal endothelial
cells (CECs). ROS generation measured by
20,70-dichlorofluorescein (DCF)ediacetate (DA)
fluorescence in CECs treated with 20 ng/mL
phosphate-buffered saline (PBS) or recombinant
human TNF-a for 15 minutes (A) and in CECs pre-
treated with 100 mmol/L apocynin (APO) for 30
minutes, followed by 15-minute incubation with
TNF-a (B). Western blots of p22phox (C) and ROS
generation in CECs byDCF-DAfluorescence transfected
with p22phox siRNA or control siRNA and treated with
TNF-a or PBS for 15 minutes (D). *P < 0.05,
**P< 0.01, and ***P < 0.001. nZ 6.
Wang et alWaltham, MA). cDNA was generated with the use of a
high-capacity cDNA archive kit (Life Technologies, Grand
Island, NY). Quantitative PCR was performed on a Mas-
tercycler ep realplex system (Eppendorf, Hauppauge, NY)
with the use of SYBR Green master mix (Roche Di-
agnostics, Indianapolis, IN) and primers synthesized by the
core research facility of the University of Utah. Expression
levels for TNF-a were normalized to the mean value of
internal control glyceraldehyde-3-phosphate dehydrogenase.
The primers (forward and reverse, respectively) were as
follows: mouse TNF-a, 50-TTGTCTACTCCCAGGTT-
CTCT-30 and 50-GAGGTTGACTTTCTCCTAATATG-30;
and mouse glyceraldehyde-3-phosphate dehydrogenase,332050-GGAGAAACCTGCCAAGTATGA-30 and 50-TCCTCA-
GTGTAGCCCAAGA-30.
Statistical Analysis
Significant differences between groups were determined by
analysis of variance with a post hoc protected Bonferroni
multiple comparison test. For animal studies, at least 20
laser spots were analyzed for CNV and 10 retinal sections
for DHE. Western blot or PCR analyses included six to
eight retinas per condition. For analysis of densitometry of
immunolabeled retinas, at least three sections taken at
60-mm intervals were examined per eye, and a total of threeFigure 3 Tumor necrosis factor (TNF)-a in-
duces choroidal endothelial cell (CEC) migration
via reactive oxygen speciesedependent Rac1
activation. CECs migrating toward 20 ng/mL TNF-a
or 20 ng/mL vascular endothelial growth factor
(VEGF) were measured after incubation with
phosphate-buffered saline (PBS; A) or 100 mmol/L
apocynin (APO; D) . Rac1 activity was analyzed in
CECs treated with TNF-a for 0, 15, or 60 minutes
(B), or pretreated with APO or PBS, followed by
15-minute incubation with TNF-a (E) and in CECs
transfected with p22phox siRNA or control siRNA
and treated with TNF-a or PBS for 15 minutes (F).
*P < 0.05, **P < 0.01, and ***P < 0.001. n Z 6
(C).
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Figure 4 Tumor necrosis factor (TNF)-a in-
duces choroidal endothelial cell (CEC) migration
via reactive oxygen speciesemediated NF-kBe
dependent Rac1 activation. Western blots of p-p65
and total p65 (A) and Rac1 activity assay (B) were
measured in CECs pretreated with 100 mmol/L
apocynin (APO) or 1 mmol/L Bay 11-7082 (Bay) for
30 minutes, followed by 15-minute incubation
with 20 ng/mL TNF-a or phosphate-buffered sa-
line. C: Western blots of p-p65 and total p65,
Rac1, and b-actin in CECs transfected with siRNA
targeting human Rac1 gene or control siRNA. D:
Migrated CECs toward TNF-a or PBS were measured
in CECs incubated with Bay 11-7082 or dimethyl
sulfoxide. *P < 0.05, **P < 0.01. n Z 6.
Rap1 Inhibits TNF-aeInduced ROS Signalseyes were used for each condition. For in vitro studies, each
experimental condition included an n Z 6 to 9, and each
experiment was performed three times. Results were
calculated as means  SEM. P < 0.05 was considered
statistically significant.
Results
Up-Regulation of TNF-a Is Associated with the
Development of CNV in a Murine Model of
Laser-Induced CNV
The TNF-a mRNA level in RPE/choroids of mice was
significantly increased 5 days after laser injury compared
with unlasered mice (Figure 1A). Compared with unlasered
controls, TNF-a staining was greater in the overlying retina
of laser-treated eyes and also colocalized with isolectin-
labeled CECs within CNV (Figure 1B). Similar to previ-
ous reports,7,8 laser-induced CNV volume was significantly
reduced in mice treated with intravitreal neutralizing Ab to
mouse TNF-a (TNF-a Ab) compared with mice treated with
intravitreal isotype IgG control (Figure 1, C and D).
TNF-a Induces ROS Generation around CNV Lesions and
in Cultured CECs by Activating NADPH Oxidase
Oxidative stress is implicated in neovascular AMD, and
quenching ROS in RPE/choroids by apocynin treatment
reduced CNV volume in the laser-induced CNV model.19
We, therefore, measured ROS generation in RPE/choroids
around CNV lesions by quantifying DHE fluorescence and
found that in mice treated with intravitreal TNF-a Ab, DHE
fluorescence density was significantly decreased compared
with that in RPE/choroids from mice treated with control
intravitreal IgG (Figure 1, E and F). These results suggest
that TNF-aemediated CNV involved generation of ROS.
To study mechanisms of TNF-aeinduced ROS genera-
tion, we measured DCF fluorescence in cultured CECs
treated with TNF-a or PBS control. Compared with
PBS, TNF-a significantly increased DCF fluorescenceThe American Journal of Pathology - ajp.amjpathol.org(Figure 2A), and this was inhibited in CECs pretreated with
apocynin before stimulation with TNF-a (Figure 2B). To
determine whether TNF-aeinduced ROS generation
involved NADPH oxidase activation, CECs were transfected
with siRNA to p22phox (Figure 2C), a subunit of NADPH
oxidase, or control siRNA. Compared with control, knock-
down of p22phox with siRNA did not affect ROS generation
when CECs were treated with PBS, but significantly reduced
ROS generation in CECs treated with TNF-a (Figure 2D).
These data provide evidence that TNF-amodulated NADPH
oxidaseedependent ROS generation in CECs.
TNF-a Induces CEC Migration through NADPH
OxidaseeDependent Rac1 Activation
CEC activation and migration are early steps in the develop-
ment of CNV. To determine whether TNF-a induced CEC
migration, the number of migrated CECs toward TNF-a,
compared with VEGF or PBS, was quantified. Compared with
PBS, TNF-a induced CEC migration to a similar degree as
VEGF (Figure 3A), consistent with previous studies.23 We
previously reported that VEGF induced CEC migration by
activating Rac1, which then caused ROS generation through
activation of NADPH oxidase.17 We found in that study that
siRNA toRac1 inhibited ROS generation induced byVEGF.17
Therefore, we first determined if activation of Rac1 was
involved in TNF-aeinduced CEC migration. Rac1 activity
assays were performed in CECs treated with TNF-a for 15 or
60 minutes. Active Rac1 (GTP-Rac1) was increased in cells
treated with TNF-a, with the greater induction noted 15 mi-
nutes after treatment (Figure 3B). Knockdown of Rac1 in
CECs by siRNA transfection (Figure 4C) prevented TNF-
aeinduced CEC migration (Figure 3C). We then sought to
determine whether TNF-aeinduced CECmigration depended
on ROS signaling. CECs were incubated with apocynin to
quench intracellular ROS or control PBS. In the presence of
apocynin, the number of TNF-aetreated CECs that migrated
was significantly reduced compared with control (Figure 3D).
Pretreatment with apocynin for 30 minutes also partially
inhibited TNF-aeinduced Rac1 activation (Figure 3E),3321
Figure 5 Activation of Rap1 inhibits choroidal
endothelial cell (CEC) migration via reactive oxygen
species (ROS)emediated NF-kB and Rac1 activation.
ROS generation (A), and activation of NF-kB (p-p65)
and Rac1 (GTP-Rac1) (B) were measured in CECs
transduced with adenovirus expressing green fluo-
rescent protein (Ad-GFP) or active Rap1a (Ad-63E)
and treated with 20 ng/mL phosphate-buffered
saline (PBS) or tumor necrosis factor (TNF)-a for
15 minutes. C: Migrated CECs toward TNF-a when
CECs were incubated with 50 mmol/L 8-(4-
chlorophenylthio)adenosine (8CPT) or PBS. D: Rac1
activity assay was measured in CECs pretreated with
8CPT for 30 minutes, followed by 15-minute incu-
bation with TNF-a. **P< 0.01, ***P< 0.001 versus
PBS of Ad-GFP; yyyP < 0.001 versus tumor necrosis
factor (TNF)-a of Ad-GFP; zP< 0.05. nZ 6 to 9 (A);
n Z 6 (C). DCF-DA, 20,70-dichlorofluorescein-
diacetate.
Wang et alsupporting the thinking that ROS-triggered signaling was
upstream of Rac1 activation induced by TNF-a. Compared
with control siRNA, knockdown of p22phox inhibited TNF-
aeinduced Rac1 activation (Figure 3F), additionally sup-
porting the idea that NADPH oxidaseegenerated ROS also
activated Rac1.
Activation of NF-kB Signaling Regulates
TNF-aeMediated Rac1 Activation and CEC Migration
Activation of NF-kB is a classic signaling pathway involved
in TNF-aemediated inflammation. We determined whether
activation of NF-kB was involved in TNF-aemediated
CEC migration and Rac1 activation. CECs, pretreated with3322apocynin or PBS, were stimulated with TNF-a or control,
and phosphoeNF-kB p65 (p-p65) was measured. NF-kB
inhibitor Bay 11-7082 was used as an additional control.
The p-p65 increased by TNF-a treatment was partially
inhibited by pretreatment with apocynin, but nearly totally
inhibited by pretreatment with Bay 11-7082 (Figure 4A). In
the same cell lysates, active Rac1 induced by TNF-a was
also partially inhibited by apocynin and blocked by pre-
treatment with Bay 11-7082 (Figure 4B). In CECs trans-
fected with Rac1 siRNA, TNF-aeinduced p-p65 was not
decreased compared with control siRNA (Figure 4C),
indicating Rac1 activation is the downstream component in
this signaling pathway. Furthermore, inhibition of NF-kB
by Bay 11-7208 significantly inhibited TNF-aeinducedFigure 6 Activation of Rap1 by 8-(4-
chlorophenylthio)adenosine (8CPT) reduces
choroidal neovascularization (CNV) volume and
NF-kB and Rac1 activation in choroidal endothelial
cells (ECs) in the laser-induced CNV model. CNV
volume (A), dihydroethidium (DHE) staining in
retinal pigment epithelium (RPE)/choroids (B),
and immunostaining of p-p65 and GTP-Rac1 (CeE)
in lectin-stained choroidal ECs (CECs) around CNV
lesions of mice injected with 0.5 mL phosphate-
buffered saline (PBS) þ 50 ng IgG, 20.5 mmol/L
8CPT þ 50 ng IgG, 50 ng tumor necrosis factor
(TNF)-a antibody (Ab) þ 0.5 mL PBS, and 20.5
mmol/L 8CPT þ 50 ng TNF-a Ab. C: Representative
images of IgG þ PBS treated eyes. D and E:
Densitometry of immunofluorescence of p-p65 and
GTP. *P < 0.05, **P < 0.01, and ***P < 0.001
versus PBS þ IgG. n Z 20 (A and B); n Z 8 (D
and E). GCL, ganglion cell layer; INL, inner nuclear
layer; IPL, inner plexiform layer; ONL, outer
nuclear layer.
ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Diagram illustrating the hypothetical signaling pathway and
feed-forward loop in inflammation- and oxidative stresseregulated
choroidal endothelial cell (CEC) migration and choroidal neovascularization
(CNV) formation. ROS, reactive oxygen species; TNF, tumor necrosis factor;
VEGF, vascular endothelial growth factor.
Rap1 Inhibits TNF-aeInduced ROS SignalsCEC migration (Figure 4D). Altogether, these data suggest
that intracellular ROS generation by TNF-a, mediating
Rac1 activation downstream of NF-kB, ultimately results in
decreased CEC migration.
Activation of Rap1 Inhibits TNF-aeInduced CEC
Migration and CNV Formation by Inhibiting
ROS-Dependent NF-kB and Rac1 Activation
We previously found that expression of active Rap1a, but not
active Rap1b, inhibited NADPH oxidaseedependent ROS
generation in RPE.21 Herein, we determined if activated Rap1
could inhibit TNF-aeinduced ROS generation in CECs and
reduce CEC migration. CECs were incubated with an adeno-
virus expressing either GFP (Ad-GFP) or active Rap1a (Ad-
63E). Forty-eight hours after viral transduction, intracellular
ROS generation measured with the DCF-diacetate assay was
significantly reduced in CECs transduced with Ad-63E and
treated with PBS (Figure 5A), consistent with our published
data.21 Also, in CECs overexpressing active Rap1a and treated
with TNF-a, ROS was significantly inhibited compared with
CECs treated with TNF-a and control adenovirus, Ad-GFP. In
a parallel experiment, TNF-aeinduced p-p65 and GTP-Rac1
were also inhibited in CECs transduced with Ad-63E
(Figure 5B). These data support the thinking that active
Rap1a inhibited ROS, NF-kB, and Rac1. Treatment with Bay
11-7082 did not reduce ROS generation induced by TNF-a
treatment (data not shown), providing support that ROS
generation was upstream of NF-kB activation. Activation of
Rap1 by 8CPT significantly reduced the number of migratingThe American Journal of Pathology - ajp.amjpathol.orgTNF-aestimulated CECs compared with control (Figure 5C).
8CPT treatment also inhibited TNF-aemediated Rac1 acti-
vation (Figure 5D). Collectively, our studies provide evidence
that activation of Rap1 in CECs inhibited TNF-aeinduced
CEC migration by reducing ROS-mediated NF-kBe
dependent Rac1 activation.
We then tested the hypothesis that Rap1 activation
inhibited TNF-aeinduced activation of NF-kB and Rac1 in
choroidal vessels by reducing ROS in vivo. Compared with
control intravitreal PBS þ IgG, mice in the laser-induced
CNV model treated with intravitreal injections of 8CPT þ
IgG, TNF-a Ab þ PBS, or TNF-a Ab þ 8CPT had
significantly reduced CNV volumes (Figure 6A) and density
of DHE fluorescence in RPE/choroids around CNV lesions
(Figure 6B). There was no difference in CNV volume or
DHE densities in eyes that received intravitreal TNF-a Ab
þ 8CPT compared with either 8CPT þ IgG or TNF-a Ab þ
PBS injections. Immunostaining of isolectin-stained ECs
with p-p65 or GTP-Rac1 (Figure 6C) showed significantly
reduced p-p65 (Figure 6D) and GTP-Rac1 (Figure 6E) in
RPE/choroids after intravitreal injection of TNF-a Ab or
8CPT, but no additional decrease in p-p65 and GFP-Rac1 in
RPE/choroids treated with both 8CPT and TNF-a Ab
compared with 8CPT þ IgG or TNF-a Ab þ PBS. The data
shown in Figures 5 and 6 provide evidence that activation of
Rap1 with 8CPT inhibits CEC migration and CNV forma-
tion mediated through TNF-aeinduced ROS and down-
stream activation of NF-kBedependent Rac1.Discussion
Neovascular AMD is a complex disease that involves
interactions of several pathways, including those involving
inflammation,9,24 oxidation,25 hypoxia,5 aging,26 and
potentially lipid- or cholesterol-related events.27 Many of
these pathways lead to biological processes involving the
loss of RPE barrier integrity and the activation of CECs
before the development of CNV that causes vision loss in
human AMD. Ideally, understanding and addressing the
mechanisms of early steps involved in neovascular AMD to
prevent compromise of RPE barrier integrity and activation
of CECs would be important to prevent vision loss from
neovascular AMD. VEGF is involved in early steps
involving angiogenesis, but treatments to inhibit VEGF are
successful in <50% of patients with neovascular AMD.2
TNF-a is an inflammatory cytokine that has been reported
in the development of CNV in the murine lasereinduced
CNV model7 and in human neovascular AMD.28 However,
inhibition of TNF-a with a systemic antieTNF-a agent
infliximab in humans was associated with uveal melanomas,
raising possible safety concerns of malignant transformation
of benign choroidal nevi.29 Therefore, we sought to under-
stand the mechanisms involved in these processes.
By using the mouse laser-induced CNV model, we
found that laser injury increased TNF-a expression in3323
Wang et alRPE/choroids, and that TNF-a colocalized with lectin-
stained CECs within the CNV lesion and those migrating
toward the CNV. Inhibition of TNF-a bioactivity by intra-
vitreal TNF-a Ab reduced CNV volume in association with
decreased ROS in RPE/choroids around CNV lesions. In
cultured human CECs, TNF-a induced NADPH oxidasee
dependent ROS generation. Intracellular ROS can function
as second messengers to activate signaling pathways
involved in physiological30 and pathological31 processes. In
CECs, TNF-a induced CEC migration, and quenching ROS
by pretreatment with apocynin significantly inhibited TNF-ae
mediated CEC migration. The results in our study support the
thinking that TNF-a contributed to CNV formation by medi-
ating ROS-dependent CEC activation and migration.
The Rho GTPase protein Rac1 regulates angiogenesis,
cell migration, and invasion.32 Rac1 activity is controlled by
guanine nucleotide exchange factors, which exchange GDP
for GTP to activate Rac1, and GTPase-activating proteins,
which convert GTP to GDP to inactivate Rac1. Inhibition of
Rac1 activity emerges as a therapeutic target in cancer by
inhibiting angiogenesis and metastasis. In cultured CECs,
we previously showed that VEGF induced CEC migration
by activating Rac1, which was upstream of activated
NADPH oxidase.17 Herein, TNF-aeinduced CEC migra-
tion was also increased via a mechanism involving Rac1
activation. However, TNF-aeinduced Rac1 activation
appeared downstream of ROS generation in the current
study. Our findings suggest a feed-forward loop that aug-
ments CEC migration by two pathways involving Rac1
activation through the inflammatory cytokine, TNF-a, and
the angiogenic factor, VEGF.
NF-kB activation is implicated in TNF-aemediated
inflammation.33 A recent study provides evidence that
NF-kB activation promotes glioma cell invasion in parallel
signaling with Rac1 activation.34 Therefore, we tested
whether activation of NF-kB was involved in TNF-ae
mediated CEC migration. Our data showed that TNF-a
activated NF-kB in CECs via ROS-dependent signaling.
Inhibition of NF-kB by a pharmacological approach
inhibited TNF-aeinduced CEC migration and Rac1 acti-
vation. However, knockdown of Rac1 in CECs did not reduce
TNF-aemediated NF-kB activation, providing evidence
that TNF-aeinduced activation of NF-kB, mediated by
NADPH oxidase, generated ROS upstream of Rac1 acti-
vation. These findings suggest additional regulatory
mechanisms from those recently reported,35 in which
NF-kB activation during inflammation was found down-
stream of Rac1.
In cultured RPE, we previously found that activation of
Rap1 by pharmacological and genetic approaches inhibited
NADPH oxidaseegenerated ROS by interfering with as-
sembly of NADPH subunits.21 Herein, we provide evidence
that activation of Rap1 through 8CPT can modulate the
effects of TNF-a or VEGF on CEC migration and CNV
formation through several steps preventing ROS-triggered
NF-kB/Rac1 activation.3324In summary, we demonstrate evidence that TNF-ae
mediated CEC activation and migration occurred by ROS-
triggered NF-kBedependent activation of Rac1 (Figure 7).
Preclinical models do not reflect the complexity in neovascular
AMD; yet, the models are helpful in assessing outcomes
related to injury, inflammation, and oxidation. Our results,
along with previous studies, suggest a way in which angio-
genic VEGF and inflammatory TNF-a can overwhelm ho-
meostatic mechanisms and thereby allow CNV formation by
generating a feed-forward loop. Hypoxia-induced VEGF ac-
tivates NADPH oxidase through Rac1 to generate intracellular
ROS. The inflammatory cytokine TNF-a also acts through
NADPH oxidase to generate ROS, which, in turn, through
NF-kB, activates Rac1. The biological events after these
signaling effects are CEC migration and CNV formation.
Thus, Rap1 activation can inhibit CNV induced through
VEGF and TNF-a (Figure 7) at several steps.Acknowledgment
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